Mike Doustdar has prioritized aggressive growth strategies for Novo Nordisk, betting on Ozempic and new drugs to counter competition. After 9,000 job cuts and revenue guidance cuts, he remains confident in the company’s resilience, citing unmet patient needs and a diversified pipeline. Doustdar’s leadership, marked by bold decisions like cutting guidance and embracing 10% sales declines, reflects his belief in calculated risks.

Novo’s Wegovy pill sales surged to 3 million prescriptions, defying rivals like Eli Lilly. Despite margin pressure from U.S. price cuts, Doustdar eyes mergers and acquisitions to diversify beyond obesity drugs, aiming for transformational deals larger than Pfizer’s $10bn Metsera deal. With semaglutide dominating future revenue, Novo explores cardiovascular and metabolic treatments, though investor skepticism lingers over post-2030 strategy.

Doustdar’s mantra—“arrogance kills”—drives a lean, focused approach to revive Novo’s fortunes.